Large Scale Identification of Variant Proteins in Glioma Stem Cells

Ekaterina Mostovenko, Ákos Végvári, Melinda Rezeli, Cheryl F. Lichti, David Fenyö, Qianghu Wang, Frederick F. Lang, Erik P. Sulman, K. Barbara Sahlin, György Marko-Varga, Carol L. Nilsson

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Glioblastoma (GBM), the most malignant of primary brain tumors, is a devastating and deadly disease, with a median survival of 14 months from diagnosis, despite standard regimens of radical brain tumor surgery, maximal safe radiation, and concomitant chemotherapy. GBM tumors nearly always re-emerge after initial treatment and frequently display resistance to current treatments. One theory that may explain GBM re-emergence is the existence of glioma stemlike cells (GSCs). We sought to identify variant protein features expressed in low passage GSCs derived from patient tumors. To this end, we developed a proteomic database that reflected variant and nonvariant sequences in the human proteome, and applied a novel retrograde proteomic workflow, to identify and validate the expression of 126 protein variants in 33 glioma stem cell strains. These newly identified proteins may harbor a subset of novel protein targets for future development of GBM therapy.

Original languageEnglish (US)
Pages (from-to)73-79
Number of pages7
JournalACS Chemical Neuroscience
Volume9
Issue number1
DOIs
StatePublished - Jan 17 2018
Externally publishedYes

Fingerprint

Glioblastoma
Stem cells
Glioma
Tumors
Stem Cells
Brain Neoplasms
Proteomics
Brain
Proteins
Chemotherapy
Workflow
Proteome
Ports and harbors
Surgery
Neoplasms
Therapeutics
Databases
Radiation
Drug Therapy
Survival

Keywords

  • bioinformatics
  • GBM
  • Glioblastoma
  • parallel reaction monitoring
  • precision medicine
  • protein quantification
  • protein single amino acid variants
  • proteomics
  • targeted mass spectrometry
  • transcriptomics

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Cite this

Mostovenko, E., Végvári, Á., Rezeli, M., Lichti, C. F., Fenyö, D., Wang, Q., ... Nilsson, C. L. (2018). Large Scale Identification of Variant Proteins in Glioma Stem Cells. ACS Chemical Neuroscience, 9(1), 73-79. https://doi.org/10.1021/acschemneuro.7b00362

Large Scale Identification of Variant Proteins in Glioma Stem Cells. / Mostovenko, Ekaterina; Végvári, Ákos; Rezeli, Melinda; Lichti, Cheryl F.; Fenyö, David; Wang, Qianghu; Lang, Frederick F.; Sulman, Erik P.; Sahlin, K. Barbara; Marko-Varga, György; Nilsson, Carol L.

In: ACS Chemical Neuroscience, Vol. 9, No. 1, 17.01.2018, p. 73-79.

Research output: Contribution to journalArticle

Mostovenko, E, Végvári, Á, Rezeli, M, Lichti, CF, Fenyö, D, Wang, Q, Lang, FF, Sulman, EP, Sahlin, KB, Marko-Varga, G & Nilsson, CL 2018, 'Large Scale Identification of Variant Proteins in Glioma Stem Cells', ACS Chemical Neuroscience, vol. 9, no. 1, pp. 73-79. https://doi.org/10.1021/acschemneuro.7b00362
Mostovenko E, Végvári Á, Rezeli M, Lichti CF, Fenyö D, Wang Q et al. Large Scale Identification of Variant Proteins in Glioma Stem Cells. ACS Chemical Neuroscience. 2018 Jan 17;9(1):73-79. https://doi.org/10.1021/acschemneuro.7b00362
Mostovenko, Ekaterina ; Végvári, Ákos ; Rezeli, Melinda ; Lichti, Cheryl F. ; Fenyö, David ; Wang, Qianghu ; Lang, Frederick F. ; Sulman, Erik P. ; Sahlin, K. Barbara ; Marko-Varga, György ; Nilsson, Carol L. / Large Scale Identification of Variant Proteins in Glioma Stem Cells. In: ACS Chemical Neuroscience. 2018 ; Vol. 9, No. 1. pp. 73-79.
@article{534095b02bcf46a8a30af65a89713041,
title = "Large Scale Identification of Variant Proteins in Glioma Stem Cells",
abstract = "Glioblastoma (GBM), the most malignant of primary brain tumors, is a devastating and deadly disease, with a median survival of 14 months from diagnosis, despite standard regimens of radical brain tumor surgery, maximal safe radiation, and concomitant chemotherapy. GBM tumors nearly always re-emerge after initial treatment and frequently display resistance to current treatments. One theory that may explain GBM re-emergence is the existence of glioma stemlike cells (GSCs). We sought to identify variant protein features expressed in low passage GSCs derived from patient tumors. To this end, we developed a proteomic database that reflected variant and nonvariant sequences in the human proteome, and applied a novel retrograde proteomic workflow, to identify and validate the expression of 126 protein variants in 33 glioma stem cell strains. These newly identified proteins may harbor a subset of novel protein targets for future development of GBM therapy.",
keywords = "bioinformatics, GBM, Glioblastoma, parallel reaction monitoring, precision medicine, protein quantification, protein single amino acid variants, proteomics, targeted mass spectrometry, transcriptomics",
author = "Ekaterina Mostovenko and {\'A}kos V{\'e}gv{\'a}ri and Melinda Rezeli and Lichti, {Cheryl F.} and David Feny{\"o} and Qianghu Wang and Lang, {Frederick F.} and Sulman, {Erik P.} and Sahlin, {K. Barbara} and Gy{\"o}rgy Marko-Varga and Nilsson, {Carol L.}",
year = "2018",
month = "1",
day = "17",
doi = "10.1021/acschemneuro.7b00362",
language = "English (US)",
volume = "9",
pages = "73--79",
journal = "ACS Chemical Neuroscience",
issn = "1948-7193",
publisher = "American Chemical Society",
number = "1",

}

TY - JOUR

T1 - Large Scale Identification of Variant Proteins in Glioma Stem Cells

AU - Mostovenko, Ekaterina

AU - Végvári, Ákos

AU - Rezeli, Melinda

AU - Lichti, Cheryl F.

AU - Fenyö, David

AU - Wang, Qianghu

AU - Lang, Frederick F.

AU - Sulman, Erik P.

AU - Sahlin, K. Barbara

AU - Marko-Varga, György

AU - Nilsson, Carol L.

PY - 2018/1/17

Y1 - 2018/1/17

N2 - Glioblastoma (GBM), the most malignant of primary brain tumors, is a devastating and deadly disease, with a median survival of 14 months from diagnosis, despite standard regimens of radical brain tumor surgery, maximal safe radiation, and concomitant chemotherapy. GBM tumors nearly always re-emerge after initial treatment and frequently display resistance to current treatments. One theory that may explain GBM re-emergence is the existence of glioma stemlike cells (GSCs). We sought to identify variant protein features expressed in low passage GSCs derived from patient tumors. To this end, we developed a proteomic database that reflected variant and nonvariant sequences in the human proteome, and applied a novel retrograde proteomic workflow, to identify and validate the expression of 126 protein variants in 33 glioma stem cell strains. These newly identified proteins may harbor a subset of novel protein targets for future development of GBM therapy.

AB - Glioblastoma (GBM), the most malignant of primary brain tumors, is a devastating and deadly disease, with a median survival of 14 months from diagnosis, despite standard regimens of radical brain tumor surgery, maximal safe radiation, and concomitant chemotherapy. GBM tumors nearly always re-emerge after initial treatment and frequently display resistance to current treatments. One theory that may explain GBM re-emergence is the existence of glioma stemlike cells (GSCs). We sought to identify variant protein features expressed in low passage GSCs derived from patient tumors. To this end, we developed a proteomic database that reflected variant and nonvariant sequences in the human proteome, and applied a novel retrograde proteomic workflow, to identify and validate the expression of 126 protein variants in 33 glioma stem cell strains. These newly identified proteins may harbor a subset of novel protein targets for future development of GBM therapy.

KW - bioinformatics

KW - GBM

KW - Glioblastoma

KW - parallel reaction monitoring

KW - precision medicine

KW - protein quantification

KW - protein single amino acid variants

KW - proteomics

KW - targeted mass spectrometry

KW - transcriptomics

UR - http://www.scopus.com/inward/record.url?scp=85040656011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040656011&partnerID=8YFLogxK

U2 - 10.1021/acschemneuro.7b00362

DO - 10.1021/acschemneuro.7b00362

M3 - Article

VL - 9

SP - 73

EP - 79

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 1

ER -